News coverage about Cynosure (NASDAQ:CYNO) has been trending somewhat positive on Saturday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cynosure earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 46.0571253019854 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

Shares of Cynosure (NASDAQ CYNO) remained flat at $$66.00 during midday trading on Friday. The company has a current ratio of 3.28, a quick ratio of 2.54 and a debt-to-equity ratio of 0.04. Cynosure has a 1-year low of $39.90 and a 1-year high of $66.65.

TRADEMARK VIOLATION WARNING: “Cynosure (CYNO) Given Media Impact Score of 0.09” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at

Cynosure Company Profile

Cynosure, Inc develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health.

Insider Buying and Selling by Quarter for Cynosure (NASDAQ:CYNO)

Receive News & Ratings for Cynosure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure and related companies with Analyst Ratings Network's FREE daily email newsletter.